For over 30 years, Celerion (www.celerion.com) has been a premier leader in laboratory and clinical services, providing critical early phase development support for emerging COVID-19 therapies, with a full range of laboratory analysis techniques to quantify and characterize small molecule and biological drugs, including antibodies and vaccines.

COVID-19 PATIENT TESTING

Celerion's first priority is the safety of our community, staff and patients via rapid sampling and testing conducted from our US and EU clinics and laboratories. A comprehensive panel of proprietary, validated clinical and bioanalytical quantitative polymerase chain reaction (qPCR) viral detection and viral load measurement and antibody binding/neutralizing assays to monitor specific SAR-CoV2 antibody responses to ensure continuous clinical trial operations in a safe environment.

COVID-19 ASSAY DEVELOPMENT

Celerion's customized bioanalytical assay development approach ranges from discovery, exploratory to fully validated biomarker and efficacy assays to monitor the immunological responses to potential products. These comprehensive laboratory services provide a one-stop service backed by experienced molecular chemists to meet the challenges involved in understanding immune response to drugs targeted against COVID-19.

OUR EXPERTISE INCLUDES:

qPCR testing • Viral detection and quantitative viral load measurement
Ligand binding methods (LBA) • Antibody detection for screening
Ligand binding methods • Ab Neutralizing Assays/Ab Titer Assays
ELISpot analysis • Cell-mediated cytokine immune response (e.g. IFN-γ, granzyme B etc.)
Flow Cytometry assays • Cellular profiling (T, B, NK cells), vaccine-induced T-cell response
Cell-based assays /(LBA) • Neutralizing Ab Measurements
Biomarker Multiplex assays • Cytokine panels (IL-2, IL-6, IL-7, G-CSF, IP-10/CXCL10, MCP-1, MIP-1°, TNF-a, MCP-3, IL-1ra, IFN-g)